Frequent EGFR mutations in brain metastases of lung adenocarcinoma

No abstract is available for this paper.

• Publication year

  2006

• Venue

  International Journal of Cancer

• Publication date

  2006-09-15

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/ijc.21940PMID 16642476
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers

  2006cited by this paper
• Frequent EGFR mutations in noninvasive bronchioloalveolar carcinoma

  2006cited by this paper
• Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers.

  2006cited by this paper
• EGFR tyrosine kinase domain mutations are detected in histologically normal respiratory epithelium in lung cancer patients.

  2005cited by this paper
• EGFR Mutation Is Specific for Terminal Respiratory Unit Type Adenocarcinoma

  2005cited by this paper
• Identification of EGFR kinase domain mutations among lung cancer patients in China: implication for targeted cancer therapy

  2005cited by this paper
• Epidermal growth factor receptor activating mutations in Spanish gefitinib-treated non-small-cell lung cancer patients.

  2005cited by this paper
• Mutations of the epidermal growth factor receptor gene in atypical adenomatous hyperplasia and bronchioloalveolar carcinoma of the lung.

  2005cited by this paper
• Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib.

  2005cited by this paper
• EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment.

  2005cited by this paper
• Gefitinib is active in patients with brain metastases from non-small cell lung cancer and response is related to skin toxicity.

  2005cited by this paper
• Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.

  2004cited by this paper
• Treatment of brain metastases from non-small-cell lung cancer (NSCLC): radiotherapy.

  2004cited by this paper
• EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy

  2004cited by this paper
• High Frequency of Epidermal Growth Factor Receptor Mutations with Complex Patterns in Non–Small Cell Lung Cancers Related to Gefitinib Responsiveness in Taiwan

  2004cited by this paper
• Mutations of the Epidermal Growth Factor Receptor Gene in Lung Cancer

  2004influential reference
• Anticancer drugs: To the rescue?

  2004cited by this paper
• Gefitinib in patients with brain metastases from non-small-cell lung cancer: review of 15 clinical cases.

  2004cited by this paper
• Pathology and genetics of tumours of the lung , pleura, thymus and heart

  2004cited by this paper
• Epidermal growth factor receptor: mechanisms of activation and signalling.

  2003cited by this paper
• Epidermal growth factor receptor targeted therapy by ZD 1839 (Iressa) in patients with brain metastases from non-small cell lung cancer (NSCLC).

  2003cited by this paper
• Aberrant receptor signaling in human malignant gliomas: mechanisms and therapeutic implications.

  2001cited by this paper
• Malignant glioma: genetics and biology of a grave matter.

  2001cited by this paper
• Microsatellite alterations in serum DNA of head and neck cancer patients

  1996cited by this paper
• Frequent allelic losses on chromosomes 2q, 18q, and 22q in advanced non-small cell lung carcinoma.

  1994cited by this paper
• Loss of heterozygosity on chromosomes 3, 13, and 17 in small-cell carcinoma and on chromosome 3 in adenocarcinoma of the lung.

  1987cited by this paper

• A Systems Biology and Artificial Intelligence Approach to Unveil Brigatinib’s Pharmacological Mechanism in Brain Metastases in ALK+ Non-Small Cell Lung Cancer

  2026cites this paper
• Molecular testing and targeting for solid tumors with CNS metastases

  2025cites this paper
• Chromosome 15q15 Deletion Drives Brain Metastasis in Non-Small Cell Lung Cancer.

  2025cites this paper
• Epidermal Growth Factor Mutation Analysis in Patients With Bronchogenic Adenocarcinoma: Prevalence and Clinical Profile-Outlook From a Tertiary Care Center in India

  2025cites this paper
• Could Radiomic Signature on Chest CT Predict Epidermal Growth Factor Receptor Mutation in Non-Small-Cell Lung Cancer?

  2024cites this paper
• The Overlooked Cornerstone in Precise Medicine: Personalized Postoperative Surveillance Plan for NSCLC

  2024cites this paper
• Stereotactic radiotherapy vs whole brain radiation therapy in EGFR mutated NSCLC: Results & reflections from the prematurely closed phase III HYBRID trial.

  2024cites this paper
• Cerebrospinal fluid ctDNA testing shows an advantage over plasma ctDNA testing in advanced non-small cell lung cancer patients with brain metastases

  2024cites this paper
• Molecular evolution of central nervous system metastasis and therapeutic implications.

  2024cites this paper
• The Use of Liquid Biopsy in the Molecular Analysis of Plasma Compared to the Tumour Tissue from a Patient with Brain Metastasis: A Case Report

  2023cites this paper
• Comparative Efficacy of ALK Inhibitors for Treatment-Naïve ALK-Positive Advanced Non-Small Cell Lung Cancer with Central Nervous System Metastasis: A Network Meta-Analysis

  2023cites this paper
• Brain metastasis screening in the molecular age

  2023cites this paper
• Factors Affecting 2-Year Survival in Patients With Non–Small Cell Lung Cancer Brain Metastases: Evidence from Indonesia’s National Cancer Center, Jakarta, Indonesia

  2023cites this paper
• Afatinib overcoming resistance to icotinib and osimertinib in NSCLC with leptomeningeal metastasis in patients with acquired EGFR L858R/T790M or L858R/S768I mutations: Two case reports

  2023cites this paper
• Métastases du système nerveux central

  2023cites this paper
• Genomic Profiling Identifies Putative Pathogenic Alterations in NSCLC Brain Metastases

  2022cites this paper
• Epidermal growth factor receptor mutations and brain metastases in non-small cell lung cancer

  2022cites this paper
• Resistance to TKIs in EGFR-Mutated Non-Small Cell Lung Cancer: From Mechanisms to New Therapeutic Strategies

  2022cites this paper
• Journal Pre-proof Genomic profiling identifies putative pathogenic alterations in non-small cell lung cancer brain metastases

  2022cites this paper
• Heterogeneity and Clinical Effect of Epidermal Growth Factor Receptor in Primary Lung and Brain Metastases of Nonsmall Cell Lung Cancer.

  2022cites this paper
• Emerging Systemic Treatment Perspectives on Brain Metastases: Moving Toward a Better Outlook for Patients.

  2022cites this paper
• EGFR mutation is not a prognostic factor for CNS metastasis in curatively resected lung adenocarcinoma patients.

  2022cites this paper
• 肺癌脑膜转移癌诊疗的研究进展

  2022cites this paper
• Hippocampal Metastasis Rate Based on Non-Small Lung Cancer TNM Stage and Molecular Markers

  2022cites this paper
• Expression of pannexin1 in brain metastases derived from lung cancer

  2021cites this paper
• Vimentin expression status is a potential biomarker for brain metastasis development in EGFR-mutant NSCLC patients

  2021cites this paper
• Precision medicine biomarkers in brain metastases: applications, discordances, and obstacles

  2021cites this paper
• Molecular Profiles of Brain Metastases: A Focus on Heterogeneity

  2021cites this paper
• Systematic review and meta-analysis of lung cancer brain metastasis and primary tumor receptor expression discordance

  2021cites this paper
• Whole-Brain Radiotherapy Can Improve the Survival of Patients with Multiple Brain Metastases from Non-Small Cell Lung Cancer Treated by Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors

  2020cites this paper
• Contrast-enhanced T1-weighted image radiomics of brain metastases may predict EGFR mutation status in primary lung cancer

  2020cites this paper
• Association of metastatic pattern and molecular status in stage IV non-small cell lung cancer adenocarcinoma

  2020cites this paper
• Tyrosine Kinase Inhibitors Could Be Effective Against Non-small Cell Lung Cancer Brain Metastases Harboring Uncommon EGFR Mutations

  2020cites this paper
• 非小细胞肺癌原发灶与转移部位驱动基因状态一致性的研究进展

  2020cites this paper
• A case-control study on prognosis between EGFR gene mutant-and wild-type non- small cell lung cancer with brain metastasis

  2020cites this paper
• Whole-exome sequencing identifies somatic mutations associated with lung cancer metastasis to the brain

  2020cites this paper
• A study on different therapies and prognosis-related factors for brain metastases in lung adenocarcinoma patients with driver mutation

  2020cites this paper
• La prise en charge des métastases cérébrales du cancer bronchique

  2020cites this paper
• Pemetrexed in the Treatment of Leptomeningeal Metastasis in Patients With EGFR-mutant Lung Cancer.

  2019cites this paper
• Discordance of epidermal growth factor receptor mutation between primary lung tumor and paired distant metastases in non-small cell lung cancer: A systematic review and meta-analysis

  2019cites this paper
• Molecular heterogeneity in lung cancer: from mechanisms of origin to clinical implications

  2019cites this paper
• Synchronicity of genetic variants between primary sites and metastatic lymph nodes, and prognostic impact in nodal metastatic lung adenocarcinoma

  2019cites this paper
• Brain MRI imaging characteristics predict treatment response and outcome in patients with de novo brain metastasis of EGFR-mutated NSCLC

  2019cites this paper
• Management of leptomeningeal metastases in non-small cell lung cancer

  2019cites this paper
• Management of CNS metastases in patients with EGFR mutation-positive NSCLC

  2019cites this paper
• The relationship between EGFR mutation and metastasis pattern in lung adenocarcinoma

  2019cites this paper
• Discordance of Epidermal Growth Factor Receptor Mutation between Brain Metastasis and Primary Non-Small Cell Lung Cancer

  2019cites this paper
• Central Nervous System Metastases in Lung Cancer Patients: From Prevention to Diagnosis and Treatment

  2019cites this paper
• Driver genes as predictive indicators of brain metastasis in patients with advanced NSCLC: EGFR, ALK, and RET gene mutations

  2019cites this paper
• Clinical Validation of Discordant Trunk Driver Mutations in Paired Primary and Metastatic Lung Cancer Specimens.

  2019cites this paper
• Risk factors for brain metastases in patients with non–small‐cell lung cancer

  2018cites this paper
• Neoplastic meningitis in solid tumors: from diagnosis to personalized treatments

  2018cites this paper
• Management of Brain Metastases in Epidermal Growth Factor Receptor Mutant Non-Small-Cell Lung Cancer

  2018cites this paper
• Efficacy of brain radiotherapy plus EGFR-TKI for EGFR-mutated non-small cell lung cancer patients who develop brain metastasis

  2018cites this paper
• Clinical factors associated with mortality within three months after radiosurgery of asymptomatic brain metastases from non-small cell lung cancer

  2018cites this paper
• The impact of EGFR mutations on the incidence and survival of stages I to III NSCLC patients with subsequent brain metastasis

  2018cites this paper
• Diffusion-Weighted Imaging of Brain Metastasis from Lung Cancer: Correlation of MRI Parameters with the Histologic Type and Gene Mutation Status

  2018cites this paper
• Early stage non-small cell lung cancer patients need brain imaging regardless of symptoms

  2018cites this paper
• Characterization of genetic alterations in brain metastases from non‐small cell lung cancer

  2018cites this paper
• Potential Molecular Signatures Predictive of Lung Cancer Brain Metastasis

  2018cites this paper
• Multiple primary lung cancer versus intrapulmonary metastatic cancer: A case of multiple pulmonary nodules

  2018cites this paper
• Clinicopathological and genetic characteristics associated with brain metastases from lung adenocarcinoma and utility as prognostic factors

  2018influential citation
• MRI Parameters with the Histologic Type Metastasis from Lung Cancer: Correlation of Diffusion-Weighted Imaging of Brain

  2018cites this paper
• Brain Metastases in Oncogene-Addicted Non-Small Cell Lung Cancer Patients: Incidence and Treatment

  2018cites this paper
• Personalized medicine in brain metastases: a plea for more translational studies.

  2018cites this paper
• Efficacy of nano‐particulated, water‐soluble erlotinib against intracranial metastases of EGFR‐mutant lung cancer

  2018cites this paper
• Heterogeneity in Lung Cancer

  2018cites this paper
• Afatinib in the first-line treatment of patients with non-small cell lung cancer: clinical evidence and experience

  2018cites this paper
• Therapeutic Effect of First-line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI) Combined with Whole Brain Radiotherapy on Patients with EGFR Mutation-positive Lung Adenocarcinoma and Brain Metastases

  2018cites this paper
• EGFR copy number alterations in primary tumors, metastatic lymph nodes, and recurrent and multiple primary tumors in oral cavity squamous cell carcinoma

  2017cites this paper
• Recurrently Mutated Genes Differ between Leptomeningeal and Solid Lung Cancer Brain Metastases

  2017cites this paper
• Treatment options for EGFR mutant NSCLC with CNS involvement-Can patients BLOOM with the use of next generation EGFR TKIs?

  2017cites this paper
• Guidelines for diagnosis , treatment and follow-up of patients with leptomeningeal metastasis from solid tumours †

  2017cites this paper
• Next-Generation Sequencing in Oncology: Genetic Diagnosis, Risk Prediction and Cancer Classification

  2017cites this paper
• Improving brain penetration of kinase inhibitors in lung cancer patients with oncogene dependency.

  2017cites this paper
• In vivo imaging xenograft models for the evaluation of anti‐brain tumor efficacy of targeted drugs

  2017cites this paper
• Leptomeningeal carcinomatosis in non-small cell lung cancer patients: A continuing challenge in the personalized treatment era.

  2017cites this paper
• Predictive factors of early distant brain failure after gamma knife radiosurgery alone in patients with brain metastases of non-small-cell lung cancer

  2017cites this paper
• Influence of EGFR mutational status on metastatic behavior in non squamous non small cell lung cancer

  2017cites this paper
• EANO-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with leptomeningeal metastasis from solid tumours.

  2017cites this paper
• Tyrosine kinase inhibitors show different anti-brain metastases efficacy in NSCLC: A direct comparative analysis of icotinib, gefitinib, and erlotinib in a nude mouse model

  2017influential citation
• EGFR as a Pharmacological Target in EGFR-Mutant Non-Small-Cell Lung Cancer: Where Do We Stand Now?

  2016cites this paper
• Brain metastases from non-small cell lung cancer : radiation therapy in the era of targeted therapies

  2016cites this paper
• Improving brain penetration of kinase inhibitors in lung cancer patients with oncogene dependency.

  2016cites this paper
• Radiotherapy plus EGFR TKIs in non‐small cell lung cancer patients with brain metastases: an update meta‐analysis

  2016cites this paper
• Gene aberrations for precision medicine against lung adenocarcinoma

  2016cites this paper
• Brain metastases in lung cancer patients : unraveling clinical questions

  2016cites this paper
• Tumour heterogeneity: principles and practical consequences

  2016influential citation
• Non-small cell lung cancer (NSCLC) and central nervous system (CNS) metastases: role of tyrosine kinase inhibitors (TKIs) and evidence in favor or against their use with concurrent cranial radiotherapy.

  2016cites this paper
• Brain Metastases from NSCLC: Radiation Therapy in the Era of Targeted Therapies

  2016cites this paper
• miRNA-197 and miRNA-184 are associated with brain metastasis in EGFR-mutant lung cancers

  2016cites this paper
• Discordance of Mutation Statuses of Epidermal Growth Factor Receptor and K-ras between Primary Adenocarcinoma of Lung and Brain Metastasis

  2016cites this paper
• The IASLC Lung Cancer Staging Project: Background Data and Proposed Criteria to Distinguish Separate Primary Lung Cancers from Metastatic Foci in Patients with Two Lung Tumors in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer

  2016cites this paper
• The Influence of Biomarker Mutations and Systemic Treatment on Cerebral Metastases from NSCLC Treated with Radiosurgery

  2016cites this paper
• First‐line epidermal growth factor receptor (EGFR)–tyrosine kinase inhibitor alone or with whole‐brain radiotherapy for brain metastases in patients with EGFR‐mutated lung adenocarcinoma

  2016cites this paper
• Leptomeningeal Metastases in Patients with NSCLC with EGFR Mutations

  2016influential citation
• The International Association for the Study of Lung Cancer Consensus Statement on Optimizing Management of EGFR Mutation-Positive Non-Small Cell Lung Cancer: Status in 2016.

  2016cites this paper
• AZD9291 in EGFR-mutant advanced non-small-cell lung cancer patients.

  2015cites this paper
• Frequency of brain metastases in non-small-cell lung cancer, and their association with epidermal growth factor receptor mutations

  2015cites this paper
• Rôle des calpaïnes extracellulaires dans la progression des adénocarcinomes lépidiques

  2015cites this paper